文献速递前列腺癌

前列腺癌放射治疗前使用水凝胶间隔物的综合综述

Comprehensive review of the use of hydrogel spacers prior to radiation therapy for prostate cancer.
PubMed 文献 · BJU Int · 2022-06-24

本文综述水凝胶间隔物对直肠剂量学和毒性的影响及置入操作要点。证据表明其使用安全、围手术期并发症有限,可减少直肠并发症,已获多项II期和III期临床试验及荟萃分析证实。性功能和肿瘤学结局数据有限,未来研究可能进一步明确其在前列腺癌管理中的作用。

要点

  • 水凝胶间隔物使用安全,围手术期并发症有限。
  • 水凝胶间隔物可减少直肠并发症,已获临床试验和荟萃分析证实。
  • 性功能和肿瘤学结局数据有限,未来研究可能进一步明确其作用。

核心结论

  • 水凝胶间隔物提供了一种低并发症的方法,可能减少前列腺癌男性放射治疗后的直肠毒性。

研究设计与样本

  • 本文为综合性叙述性综述,汇总已发表的水凝胶间隔物对直肠剂量学和毒性影响的数据,并概述置入水凝胶间隔物的实际操作。

主要发现

  • 不断积累的证据表明,使用水凝胶间隔物是安全的,且与有限的围手术期并发症相关。
  • 对直肠剂量学的影响已明确建立,使用水凝胶间隔物与减少直肠并发症相关。
  • 这些结果已获多项II期和III期临床试验及后续荟萃分析证实。

局限性

  • 性功能和肿瘤学结局数据至今有限。
  • 未来研究正在进行中,可能进一步明确水凝胶间隔物在前列腺癌管理中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To provide a comprehensive narrative review of the published data on the impact of hydrogel spacers on rectal dosimetry and toxicity and to outline the practicalities of inserting hydrogel spacers. RESULTS: A growing body of evidence suggests that the administration of hydrogel spacers is safe and is associated with limited peri-operative morbidity. The impact on rectal dosimetry has been clearly established and use of hydrogel spacers is associated with reduced rectal morbidity. These results have been corroborated by several Phase II and III clinical trials and subsequent meta-analysis. There are several areas for future research, including the role of hydrogel spacers in prostate stereotactic beam radiotherapy and post-radiotherapy local recurrence. CONCLUSIONS: Hydrogel spacers provide a low-morbidity method to potential reduce rectal toxicity after radiation therapy in men with prostate cancer. Data outlining sexual function and oncological outcomes are limited to date. Future studies, currently being conducted, may provide further clarification of the role of hydrogel spacers in prostate cancer management.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Harvey M, Ong WL, Chao M, et al. Comprehensive review of the use of hydrogel spacers prior to radiation therapy for prostate cancer. BJU Int. 2022. PMID: 35689413. doi:10.1111/bju.15821

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。